Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disor...
HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, announced that...
XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced that it has entered into a worldwide License, Dev...
SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the drug could halt disease progression and even rever...
Largest demonstration of its kind combines leading hardware, platforms, and techniques to achieve 20 times speedup over previous demonstrations Ecosys...
OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugate...
Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free...
Third asset to advance into clinical trials, validating broad potential of Launch-iT platform All subjects treated with first dose of AVX70371 Launch-...
BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by t...
Biognosys, a global leader in mass spectrometry-based proteomics solutions, announces the launch of Spectronaut® 20 and SpectroMine™ ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological ...
YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimil...
The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology1, with an init...
Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for can...
© 2025 Biopharma Boardroom. All Rights Reserved.
